Citations

Clear

278 citation(s) found for "Sy, Ethan".

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Basch, Ethan , Deal, Allison M. , Scher, Howard I. , Hudis, Clifford A. , Sabbatini, Paul , Rogak, Lauren J. , Dueck, Amylou C. , Atkinson, Thomas M. , Chou, Joanne F. , Dulko, Dorothy , Sit, Laura , Leahy, Allison Barz , Novotny, Paul J. , Fruscione, M. , Sloan, Jeff A. , Schrag, Deborah , Kris, Mark G, Rogak, Lauren , Bennett, Antonia V. , Barz, Allison, Novotny, Paul, Fruscione, Michael, Dueck, A. C. , Basch, Ethan , Deal, Allison , Kris, Mark G. , Bennett, Antonia V , Schrag, Deborah , Leahy, Allison B

Mayo Clinic

Journal of Clinical Oncology | December 8, 2015 | Volume: 34 | Issue: 6 | Pages: 557-565

10.1200/jco.2015.63.0830 | PMID 26644527 Get It

Purpose There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes is limited. Methods We randomly assigned patients receiving routine outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 common symptoms via tablet computers or to receive usual care consisting of symptom monitoring at the discretion of clinicians. Those with home computers received weekly e-mail prompts to report between visits. Treating physicians received symptom printouts at visits, and nurses received e-mail alerts when participants reported severe or worsening symptoms. The primary outcome was change in health-related quality of life (HRQL) at 6 months compared with baseline, measured by the EuroQol EQ-5D Index. Secondary endpoints included emergency room (ER) visits, hospitalizations, and survival. Results Among 766 patients allocated, HRQL improved among more participants in the intervention group than usual care (34% v 18%) and worsened among fewer (38% v 53%; P < .001). Overall, mean HRQL declined by less in the intervention group than usual care (1.4- v 7.1-point drop; P < .001). Patients receiving intervention were less frequently admitted to the ER (34% v 41%; P = .02) or hospitalized (45% v 49%; P = .08) and remained on chemotherapy longer (mean, 8.2 v 6.3 months; P = .002). Although 75% of the intervention group was alive at 1 year, 69% with usual care survived the year (P = .05), with differences also seen in quality-adjusted survival (mean of 8.7 v. 8.0 months; P = .004). Benefits were greater for participants lacking prior computer experience. Most patients receiving intervention (63%) reported severe symptoms during the study. Nurses frequently initiated clinical actions in response to e-mail alerts. Conclusion Clinical benefits were associated with symptom self-reporting during cancer care.
Diagnostic Thresholds for Quantitative REM Sleep Phasic Burst Duration, Phasic and Tonic Muscle Activity, and REM Atonia Index in REM Sleep Behavior Disorder with and without Comorbid Obstructive Sleep Apnea
McCarter, Stuart J. , Louis, Erik K. St. , Duwell, Ethan J. , Timm, Paul, Sandness, David J., Silber, Michael H. , St Louis, Erik K, Timm, Paul C, Boeve, Bradley F. , St Louis, E K , McCarter, Stuart J

Mayo Clinic

Sleep | September 30, 2014 | Volume: 37 | Issue: 10 | Pages: 1649-1662

10.5665/sleep.4074 | PMID 25197816 Get It

Allocating scarce resources in real-time to reduce heart failure readmissions: a prospective, controlled study
Amarasingham, Ruben, Patel, Parag C. , Toto, Kathleen H., Nelson, Lauren L., Swanson, Timothy S. , Moore, Billy J. , Xie, Bin , Zhang, Song , Alvarez, Kristin , Ma, Ying , Kollipara, Usha K., Drazner, Mark H. , Halm, Ethan A. , Alvarez, Kristin

Mayo Clinic

BMJ Quality & Safety | August 1, 2013 | Volume: 22 | Issue: 12 | Pages: 998-1005

10.1136/bmjqs-2013-001901 | PMID 23904506 Get It

Objective To test a multidisciplinary approach to reduce heart failure (HF) readmissions that tailors the intensity of care transition intervention to the risk of the patient using a suite of electronic medical record (EMR)-enabled programmes. Methods A prospective controlled before and after study of adult inpatients admitted with HF and two concurrent control conditions (acute myocardial infarction (AMI) and pneumonia (PNA)) was performed between 1 December 2008 and 1 December 2010 at a large urban public teaching hospital. An EMR-based software platform stratified all patients admitted with HF on a daily basis by their 30-day readmission risk using a published electronic predictive model. Patients at highest risk received an intensive set of evidence-based interventions designed to reduce readmission using existing resources. The main outcome measure was readmission for any cause and to any hospital within 30 days of discharge. Results There were 834 HF admissions in the pre-intervention period and 913 in the post-intervention period. The unadjusted readmission rate declined from 26.2% in the pre-intervention period to 21.2% in the post-intervention period (p=0.01), a decline that persisted in adjusted analyses (adjusted OR (AOR)=0.73; 95% CI 0.58 to 0.93, p=0.01). In contrast, there was no significant change in the unadjusted and adjusted readmission rates for PNA and AMI over the same period. There were 45 fewer readmissions with 913 patients enrolled and 228 patients receiving intervention, resulting in a number needed to treat (NNT) ratio of 20. Conclusions An EMR-enabled strategy that targeted scarce care transition resources to high-risk HF patients significantly reduced the risk-adjusted odds of readmission.
Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology
Basch, Ethan , Mullins, C. Daniel , Smith, Mary Lou , Coons, Stephen Joel , Sloan, Jeff A. , Wenzel, Keith W., Chauhan, Cynthia, Eppard, Wayland, Lipscomb, Joseph , Raymond, Stephen A., Spencer, Merianne, Tunis, Sean , Basch, Ethan , Abernethy, Amy P. , Reeve, Bryce B. , Frank, Elizabeth S.

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 30 | Issue: 34 | Pages: 4249-4255

10.1200/jco.2012.42.5967 | PMID 23071244 Get It

Examining the patient's subjective experience in prospective clinical comparative effectiveness research (CER) of oncology treatments or process interventions is essential for informing decision making. Patient-reported outcome (PRO) measures are the standard tools for directly eliciting the patient experience. There are currently no widely accepted standards for developing or implementing PRO measures in CER. Recommendations for the design and implementation of PRO measures in CER were developed via a standardized process including multistakeholder interviews, a technical working group, and public comments. Key recommendations are to include assessment of patient-reported symptoms as well as health-related quality of life in all prospective clinical CER studies in adult oncology; to identify symptoms relevant to a particular study population and context based on literature review and/or qualitative and quantitative methods; to assure that PRO measures used are valid, reliable, and sensitive in a comparable population (measures particularly recommended include EORTC QLQ-C30, FACT, MDASI, PRO-CTCAE, and PROMIS); to collect PRO data electronically whenever possible; to employ methods that minimize missing patient reports and include a plan for analyzing and reporting missing PRO data; to report the proportion of responders and cumulative distribution of responses in addition to mean changes in scores; and to publish results of PRO analyses simultaneously with other clinical outcomes. Twelve core symptoms are recommended for consideration in studies in advanced or metastatic cancers. Adherence to methodologic standards for the selection, implementation, and analysis/reporting of PRO measures will lead to an understanding of the patient experience that informs better decisions by patients, providers, regulators, and payers.
The Lack of Growth in Use of Coronary CT Angiography: Is It Being Appropriately Used?
Levin, David C. , Parker, Laurence, Halpern, Ethan J. , Julsrud, Paul R., Rao, Vijay M.

Mayo Clinic

American Journal of Roentgenology | March 22, 2011 | Volume: 196 | Issue: 4 | Pages: 862-867

10.2214/ajr.10.5236 | PMID 21427337 Get It

The Pediatric Subspecialty Workforce: Public Policy and Forces for Change
Jewett, Ethan Alexander, Anderson, Michael R., Gilchrist, Gerald S.

Mayo Clinic

Pediatrics | October 1, 2005 | Volume: 116 | Issue: 5 | Pages: 1192-1202

10.1542/peds.2004-2339 | PMID 16199670 Get It

Policy has not adequately addressed the unique circumstances of pediatric subspecialties, many of which are facing workforce shortages. Pediatric subspecialties, which we define to include all medical and surgical subspecialties, are discrete disciplines that differ significantly from each other and from adult medicine subspecialties. Concerns about a current shortage of pediatric subspecialists overall are driven by indicators ranging from recruitment difficulties to long wait times for appointments. The future supply of pediatric subspecialists and patient access to pediatric subspecialty care will be affected by a number of key factors or forces for change. We discuss 5 of these factors: changing physician and patient demographics; debt load and lifestyle considerations; competition among providers of subspecialty care; equitable reimbursement for subspecialty services; and policy to regulate physician supply. We also identify issues and strategies that medical and specialty societies, pediatric subspecialists, researchers, child advocates, policy makers, and others should consider in the development of subspecialty-specific workforce-policy agendas.
Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension
Lange, Leslie A. , Lange, Ethan M. , Bielak, Lawrence F. , Langefeld, Carl D. , Kardia, Sharon L.R., Royston, Patrick , Sheedy, Patrick F. , Boerwinkle, Eric , Peyser, Patricia A. , Turner, Stephen T.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | July 28, 2002 | Volume: 22 | Issue: 3 | Pages: 418-423

10.1161/hq0302.105721 | PMID 11884284 Get It

Abstract— Coronary artery disease (CAD) is the leading cause of mortality in the developed world. Although several CAD risk factors, including measures of lipid metabolism, obesity, and blood pressure, have a genetic basis, many genes for CAD susceptibility have yet to be identified. Coronary atherosclerosis is the major cause of CAD, but many with coronary atherosclerosis lack symptoms. Thus, a major limitation of using symptomatic CAD endpoints (eg, sudden coronary death, myocardial infarction) as a study outcome is substantial disease misclassification. Coronary artery calcification (CAC) is part of the atherosclerotic process and is an independent predictor of CAD endpoints. In the present study, CAC was noninvasively quantified by electron beam computed tomography. We performed genome-wide multipoint mode-of-inheritance-free linkage analysis on affected sib pairs, defined as being ≥ the 70th sex- and age-specific percentile for CAC quantity, in a sample of 29 families enriched for hypertension. Almost 95% of participants were asymptomatic for CAD. Our LOD score (log 10 odds in favor of linkage) results provide evidence that chromosomal regions 6p21.3 (maximum LOD score=2.22, P =0.00070) and 10q21.3 (maximum LOD score=3.24, P =0.000057) may harbor genes associated with subclinical coronary atherosclerosis.